Home > Rubicon Genomics Salary

Rubicon Genomics Salary

  • 70
  • 66
  • 26
Rubicon Genomics average salary is $123,157, median salary is $123,157 with a salary range from $123,157 to $123,157.
Rubicon Genomics salaries are collected from government agencies and companies. Each salary is associated with a real job position. Rubicon Genomics salary statistics is not exclusive and is for reference only. They are presented "as is" and updated regularly.
Low
123,157
Average
123,157
Median
123,157
High
123,157
Total 1 Rubicon Genomics Salaries. Sorted by Date, page 1
Ranked By:
Job Title Salaries City Year More info
Partner 123,157-123,157 New York, NY, 10001 2012 Rubicon Genomics Partner Salaries (1)
Rubicon Genomics New York, NY Salaries
Calculate how much you could earn

It's FREE. Based on your input and our analysis.     How we do it?

All fields are required for calculation accuracy.

  • We will send you an email to access your personalized report.
  • We won’t share your email address

Rubicon Genomics salary is full-time annual starting salary. Intern, contractor and hourly pay scale vary from regular exempt employee. Compensation depends on work experience, job location, bonus, benefits and other factors.

Real Jobs Salary - Salary List
Calculate Your Salary Ranking
Rubicon Genomics Jobs
See more Rubicon Genomics Jobs»
Search All Jobs

JobCompare – Find open jobs faster
Rubicon Genomics... Information
  • Rubicon Genomics, Inc
  • Industry: Biotech/Healthcare
  • City: Ann Arbor, MI
  • Rubicon Genomics is a leader in the development of improved technologies for detecting the pattern of DNA methylation in cancer cells. Rubicon has developed a superior test to non-invasively diagnose cancer and other diseases using its proprietary MethylPlex? technology to amplify the exceedingly small amounts of abnormally-methylated DNA that are released by diseased tissue into serum and urine. MethylPlex has proven sensitivity and simplicity advantages over current competitive tests for methylated DNA tumor markers. The increased technical sensitivity will enable earlier, more reliable non-invasive detection of disease as well as allow for more methylation markers to be assayed in a